{"title":"塞尔维亚狂犬病暴露后预防的现实证据:全国观察研究(2017-2019 年)。","authors":"Pavle Banović , Dragana Mijatović , Verica Simin , Nenad Vranješ , Eleftherios Meletis , Polychronis Kostoulas , Dasiel Obregon , Alejandro Cabezas-Cruz","doi":"10.1016/j.tmaid.2024.102697","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Rabies remains a deadly zoonotic disease, primarily prevalent in Eastern European countries, with a significant global burden in Asia and Africa. Post-exposure prophylaxis (PEP) is critical to prevent clinical rabies. Serbia, a country with a relatively low animal rabies incidence, has been implementing a 4-dose Essen PEP regimen for 13 years. This real-world study aimed to assess the effectiveness of the 4-dose Essen regimen, considering demographic and clinical factors, after WHO Category III exposure.</p></div><div><h3>Method</h3><p>The study included 601 patients who received the 4-dose Essen PEP and 79 who received an additional 5th dose.</p></div><div><h3>Results</h3><p>Age emerged as a critical factor influencing seroconversion rates after the 4-dose regimen, with older individuals exhibiting lower RVNA titers. Logistic regression indicated a 3.18% decrease in seroconversion odds for each added year of age. The Cox proportional hazards mixed model highlighted age-related risks, with age groups 45–60 and 75–92 at the highest risk of non-seroconversion. Human Rabies Immune Globulin (HRIG) administration was associated with lower RVNA values after the 4-dose regimen, suggesting interference with vaccine immunogenicity among people who received larger doses of HRIG.</p></div><div><h3>Conclusions</h3><p>This study provides valuable real-world evidence for rabies PEP in a non-homogeneous population with potential comorbidities. The results underscore the importance of optimizing PEP strategies, particularly in older individuals, and reconsidering HRIG dosing to improve seroconversion rates.</p></div>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"58 ","pages":"Article 102697"},"PeriodicalIF":6.3000,"publicationDate":"2024-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1477893924000115/pdfft?md5=eee77db6c216c0347676b3f70058159a&pid=1-s2.0-S1477893924000115-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Real-world evidence of rabies post-exposure prophylaxis in Serbia: Nation-wide observational study (2017–2019)\",\"authors\":\"Pavle Banović , Dragana Mijatović , Verica Simin , Nenad Vranješ , Eleftherios Meletis , Polychronis Kostoulas , Dasiel Obregon , Alejandro Cabezas-Cruz\",\"doi\":\"10.1016/j.tmaid.2024.102697\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Rabies remains a deadly zoonotic disease, primarily prevalent in Eastern European countries, with a significant global burden in Asia and Africa. Post-exposure prophylaxis (PEP) is critical to prevent clinical rabies. Serbia, a country with a relatively low animal rabies incidence, has been implementing a 4-dose Essen PEP regimen for 13 years. This real-world study aimed to assess the effectiveness of the 4-dose Essen regimen, considering demographic and clinical factors, after WHO Category III exposure.</p></div><div><h3>Method</h3><p>The study included 601 patients who received the 4-dose Essen PEP and 79 who received an additional 5th dose.</p></div><div><h3>Results</h3><p>Age emerged as a critical factor influencing seroconversion rates after the 4-dose regimen, with older individuals exhibiting lower RVNA titers. Logistic regression indicated a 3.18% decrease in seroconversion odds for each added year of age. The Cox proportional hazards mixed model highlighted age-related risks, with age groups 45–60 and 75–92 at the highest risk of non-seroconversion. Human Rabies Immune Globulin (HRIG) administration was associated with lower RVNA values after the 4-dose regimen, suggesting interference with vaccine immunogenicity among people who received larger doses of HRIG.</p></div><div><h3>Conclusions</h3><p>This study provides valuable real-world evidence for rabies PEP in a non-homogeneous population with potential comorbidities. The results underscore the importance of optimizing PEP strategies, particularly in older individuals, and reconsidering HRIG dosing to improve seroconversion rates.</p></div>\",\"PeriodicalId\":23312,\"journal\":{\"name\":\"Travel Medicine and Infectious Disease\",\"volume\":\"58 \",\"pages\":\"Article 102697\"},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2024-02-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1477893924000115/pdfft?md5=eee77db6c216c0347676b3f70058159a&pid=1-s2.0-S1477893924000115-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Travel Medicine and Infectious Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1477893924000115\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Travel Medicine and Infectious Disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1477893924000115","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
背景:狂犬病仍然是一种致命的人畜共患疾病,主要流行于东欧国家,在亚洲和非洲造成了严重的全球负担。暴露后预防 (PEP) 对于预防临床狂犬病至关重要。塞尔维亚是一个动物狂犬病发病率相对较低的国家,13 年来一直在实施 4 剂埃森 PEP 方案。这项真实世界研究旨在评估世卫组织 III 类暴露后,考虑到人口和临床因素的 4 剂埃森方案的有效性:研究包括 601 名接受了 4 剂埃森 PEP 的患者和 79 名接受了额外第 5 剂的患者:结果:年龄是影响 4 剂方案后血清转换率的关键因素,年龄较大者的 RVNA 滴度较低。逻辑回归表明,年龄每增加一岁,血清转换几率就会降低 3.18%。Cox 比例危险度混合模型突出显示了与年龄相关的风险,45-60 岁和 75-92 岁年龄组发生非血清转换的风险最高。注射人狂犬病免疫球蛋白(HRIG)与4剂量方案后较低的RVNA值有关,这表明注射较大剂量HRIG的人群的疫苗免疫原性受到干扰:这项研究为在具有潜在合并症的非同质人群中进行狂犬病 PEP 提供了宝贵的实际证据。研究结果强调了优化 PEP 策略的重要性,尤其是对老年人,并重新考虑 HRIG 剂量以提高血清转换率。
Real-world evidence of rabies post-exposure prophylaxis in Serbia: Nation-wide observational study (2017–2019)
Background
Rabies remains a deadly zoonotic disease, primarily prevalent in Eastern European countries, with a significant global burden in Asia and Africa. Post-exposure prophylaxis (PEP) is critical to prevent clinical rabies. Serbia, a country with a relatively low animal rabies incidence, has been implementing a 4-dose Essen PEP regimen for 13 years. This real-world study aimed to assess the effectiveness of the 4-dose Essen regimen, considering demographic and clinical factors, after WHO Category III exposure.
Method
The study included 601 patients who received the 4-dose Essen PEP and 79 who received an additional 5th dose.
Results
Age emerged as a critical factor influencing seroconversion rates after the 4-dose regimen, with older individuals exhibiting lower RVNA titers. Logistic regression indicated a 3.18% decrease in seroconversion odds for each added year of age. The Cox proportional hazards mixed model highlighted age-related risks, with age groups 45–60 and 75–92 at the highest risk of non-seroconversion. Human Rabies Immune Globulin (HRIG) administration was associated with lower RVNA values after the 4-dose regimen, suggesting interference with vaccine immunogenicity among people who received larger doses of HRIG.
Conclusions
This study provides valuable real-world evidence for rabies PEP in a non-homogeneous population with potential comorbidities. The results underscore the importance of optimizing PEP strategies, particularly in older individuals, and reconsidering HRIG dosing to improve seroconversion rates.
期刊介绍:
Travel Medicine and Infectious Disease
Publication Scope:
Publishes original papers, reviews, and consensus papers
Primary theme: infectious disease in the context of travel medicine
Focus Areas:
Epidemiology and surveillance of travel-related illness
Prevention and treatment of travel-associated infections
Malaria prevention and treatment
Travellers' diarrhoea
Infections associated with mass gatherings
Migration-related infections
Vaccines and vaccine-preventable disease
Global policy/regulations for disease prevention and control
Practical clinical issues for travel and tropical medicine practitioners
Coverage:
Addresses areas of controversy and debate in travel medicine
Aims to inform guidelines and policy pertinent to travel medicine and the prevention of infectious disease
Publication Features:
Offers a fast peer-review process
Provides early online publication of accepted manuscripts
Aims to publish cutting-edge papers